Clinical Characteristics and Prognoses in Pediatric Neuroblastoma with Bone or Liver Metastasis: Data from the SEER 2010-2019

Overview

Journal BMC Pediatr

Publisher Biomed Central

Specialty Pediatrics

Date 2024 Mar 8

PMID 38454422

Authors

Xudong Zhao

ZhuoFan Xu

Xiaochuan Feng

Affiliations

Soon will be listed here.

Abstract

Background: To investigate clinical characteristics, prognoses, and impacts of treatments on prognoses of neuroblastoma patients with bone or liver metastasis.

Methods: This retrospective cohort study extracted data from the Surveillance, Epidemiology, and End Results (SEER) database 2010-2019. The outcomes were 3-year cancer-specific survival (CSS) and 5-year CSS. Multivariable COX risk proportional models were established to assess the association between metastasis types and CSS. Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated.

Results: Totally 425 patients with metastatic neuroblastoma were eligible for 3-year CSS analysis and 320 for 5-year CSS analysis. For 3-year follow-up, 62 (14.59%) patients had liver metastasis alone, 289 (0.68%) had bone metastasis alone, and 74 (17.41%) had both liver and bone metastasis. For 5-year follow-up, 44 (13.75%) patients had liver metastasis alone, 223 (69.69%) had bone metastasis alone, and 53 (16.56%) had both liver and bone metastasis. Significant differences were observed in age, tumor size, surgery for the primary site, chemotherapy, radiation, brain metastasis, lung metastasis, and vital status between patients with liver metastasis alone, bone metastasis alone, and both liver and bone metastasis (all P < 0.05). Compared with patients with liver metastasis alone, patients with bone metastasis alone (HR = 2.30, 95%CI: 1.10-4.82, P = 0.028) or both (HR = 2.35, 95%CI: 1.06-5.20, P = 0.035) had significantly poorer 3-year CSS; patients with bone metastasis alone (HR = 2.32, 95%CI: 1.14-4.70, P = 0.020) or both liver and bone metastasis (HR = 2.33, 95%CI: 1.07-5.07, P = 0.032) exhibited significantly worse 5-year CSS than those with liver metastasis alone. In patients with bone metastasis, those with chemotherapy had significantly better 3-year CSS than those without (HR = 0.24, 95%CI: 0.07-0.75, P = 0.014). Among patients with liver metastasis, receiving radiation was associated with significantly worse 3-year CSS (HR = 2.00, 95%CI: 1.05-3.81, P = 0.035).

Conclusion: Compared with patients with liver metastasis alone, those with bone metastasis alone or both had poorer 3- and 5-year CSS. For patients with bone metastasis, undergoing chemotherapy was associated with better 3-year CSS. For patients with liver metastasis, receiving radiation was associated with worse 3-year CSS.

References

de la Monte S, Moore G, Hutchins G . Nonrandom distribution of metastases in neuroblastic tumors. Cancer. 1983; 52(5):915-25. DOI: 10.1002/1097-0142(19830901)52:5<915::aid-cncr2820520529>3.0.co;2-7. View

Liu S, Yin W, Lin Y, Huang S, Xue S, Sun G . Metastasis pattern and prognosis in children with neuroblastoma. World J Surg Oncol. 2023; 21(1):130. PMC: 10091559. DOI: 10.1186/s12957-023-03011-y. View

Kuroda T . Cellular kinetics of neuroblastoma and the role of surgery. Pediatr Surg Int. 2011; 27(9):913-7. DOI: 10.1007/s00383-011-2949-6. View

Kuroda T, Saeki M, Honna T, Masaki H, Tsunematsu Y . Clinical significance of intensive surgery with intraoperative radiation for advanced neuroblastoma: does it really make sense?. J Pediatr Surg. 2003; 38(12):1735-8. DOI: 10.1016/j.jpedsurg.2003.08.043. View

Zhao Q, Liu Y, Zhang Y, Meng L, Wei J, Wang B . Role and toxicity of radiation therapy in neuroblastoma patients: A literature review. Crit Rev Oncol Hematol. 2020; 149:102924. DOI: 10.1016/j.critrevonc.2020.102924. View

Imaya M, Muramatsu H, Narita A, Yamamori A, Wakamatsu M, Yoshida T . Combination chemotherapy consisting of irinotecan, etoposide, and carboplatin for refractory or relapsed neuroblastoma. Cancer Med. 2022; 11(9):1956-1964. PMC: 9089216. DOI: 10.1002/cam4.4529. View

Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F . Molecular targeting therapies for neuroblastoma: Progress and challenges. Med Res Rev. 2020; 41(2):961-1021. PMC: 7906923. DOI: 10.1002/med.21750. View

Zhang S, Zhang W, Jin M, Sun Q, Zhang Z, Qin H . Biological features and clinical outcome in infant neuroblastoma: a multicenter experience in Beijing. Eur J Pediatr. 2021; 180(7):2055-2063. DOI: 10.1007/s00431-021-03989-1. View

Tortolici F, Vumbaca S, Incocciati B, Dayal R, Aquilano K, Giovanetti A . Ionizing Radiation-Induced Extracellular Vesicle Release Promotes AKT-Associated Survival Response in SH-SY5Y Neuroblastoma Cells. Cells. 2021; 10(1). PMC: 7827279. DOI: 10.3390/cells10010107. View

10.

Salemi F, Alam W, Hassani M, Hashemi S, Azari Jafari A, Mirmoeeni S . Neuroblastoma: Essential genetic pathways and current therapeutic options. Eur J Pharmacol. 2022; 926:175030. DOI: 10.1016/j.ejphar.2022.175030. View

11.

Ahmed S, Alam W, Aschner M, Filosa R, Cheang W, Jeandet P . Marine Cyanobacterial Peptides in Neuroblastoma: Search for Better Therapeutic Options. Cancers (Basel). 2023; 15(9). PMC: 10177606. DOI: 10.3390/cancers15092515. View

12.

Caussa L, Hijal T, Michon J, Helfre S . Role of palliative radiotherapy in the management of metastatic pediatric neuroblastoma: a retrospective single-institution study. Int J Radiat Oncol Biol Phys. 2010; 79(1):214-9. DOI: 10.1016/j.ijrobp.2009.10.031. View

13.

Ducassou A, Gambart M, Munzer C, Padovani L, Carrie C, Haas-Kogan D . Long-term side effects of radiotherapy for pediatric localized neuroblastoma : results from clinical trials NB90 and NB94. Strahlenther Onkol. 2015; 191(7):604-12. DOI: 10.1007/s00066-015-0837-z. View

14.

Wei Z, Li J, Jin Y, Liu Y, Wang P, Cao Y . The application and value of radiotherapy at the primary site in patients with high-risk neuroblastoma. Br J Radiol. 2022; 95(1134):20211086. PMC: 10996409. DOI: 10.1259/bjr.20211086. View

15.

Coughlan D, Gianferante M, Lynch C, Stevens J, Harlan L . Treatment and survival of childhood neuroblastoma: Evidence from a population-based study in the United States. Pediatr Hematol Oncol. 2017; 34(5):320-330. PMC: 6764456. DOI: 10.1080/08880018.2017.1373315. View

16.

Ryan A, Akinkuotu A, Pierro A, Morgenstern D, Irwin M . The Role of Surgery in High-risk Neuroblastoma. J Pediatr Hematol Oncol. 2019; 42(1):1-7. DOI: 10.1097/MPH.0000000000001607. View

17.

Dubois S, Kalika Y, Lukens J, Brodeur G, Seeger R, Atkinson J . Metastatic sites in stage IV and IVS neuroblastoma correlate with age, tumor biology, and survival. J Pediatr Hematol Oncol. 1999; 21(3):181-9. DOI: 10.1097/00043426-199905000-00005. View

18.

Ara T, DeClerck Y . Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev. 2006; 25(4):645-57. DOI: 10.1007/s10555-006-9028-9. View

19.

Mlakar V, Morel E, Jurkovic Mlakar S, Ansari M, Gumy-Pause F . A review of the biological and clinical implications of RAS-MAPK pathway alterations in neuroblastoma. J Exp Clin Cancer Res. 2021; 40(1):189. PMC: 8188681. DOI: 10.1186/s13046-021-01967-x. View

20.

Jahangiri L . Metastasis in Neuroblastoma and Its Link to Autophagy. Life (Basel). 2023; 13(3). PMC: 10056181. DOI: 10.3390/life13030818. View